26
Participants
Start Date
September 30, 2004
Primary Completion Date
September 30, 2004
Study Completion Date
September 30, 2004
Abrika Bupropion 150 mg Extended-Released Tablet
A: Experimental Subjects received Abrika formulated products under fed conditions
Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
SFBC Ft. Myers, Inc., Fort Myers
Lead Sponsor
Actavis Inc.
INDUSTRY